nach oben

Erschienen in:

01.10.2013

Early Increase in Alveolar Macrophage Prostaglandin 15d-PGJ2 Precedes Neutrophil Recruitment into Lungs of Cytokine-Insufflated Rats

verfasst von: Ana Fernandez-Bustamante, Jelena Klawitter, Paul Wilson, Nancy D. Elkins, Amanda Agazio, Takahiro Shibata, Koji Uchida, Uwe Christians, John E. Repine

Erschienen in: Inflammation | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

ABSTRACT

Early detection and prevention is an important goal in acute respiratory distress syndrome research. We determined the concentration of the anti-inflammatory 15-deoxy-Δ^12,14-prostaglandin-J2 (15d-PGJ2) and other components of the cyclopentenone prostaglandin cascade in relation to lung inflammation in cytokine (IL-1/LPS)-insufflated rats. We found that 15d-PGJ2 levels increase in the bronchoalveolar lavage (BAL) fluid of rats insufflated with cytokines 2 h before. BAL 15d-PGJ2 increases preceded neutrophil recruitment, lung injury, and oxidative stress in the lungs of cytokine-insufflated rats. 15d-PGJ2 was localized in alveolar macrophages that decreased following cytokine insufflation. 15d-PGJ2 may constitute an early biomarker of lung inflammation and may reflect an endogenous attempt to regulate ongoing inflammation in macrophages and elsewhere after cytokine insufflation.

Phua, J., J.R. Badia, N.K. Adhikari, et al. 2009. Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. American Journal of Respiratory and Critical Care Medicine 179: 220–227.PubMedCrossRef

Villar, J., J. Blanco, J.M. Anon, et al. 2011. The ALIEN study: Incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Medicine 37: 1932–1941.PubMedCrossRef

Wind, J., J. Versteegt, J. Twisk, et al. 2007. Epidemiology of acute lung injury and acute respiratory distress syndrome in The Netherlands: A survey. Respiratory Medicine 101: 2091–2098.PubMedCrossRef

ARDS Definition Task Force T. 2012. Acute respiratory distress syndrome: The Berlin definition. JAMA: The Journal of the American Medical Association 307: 2526–2533.CrossRef

Ware, L.B., T. Koyama, D.D. Billheimer, et al. 2010. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 137: 288–296.PubMedCrossRef

Shibata, T., M. Kondo, T. Osawa, N. Shibata, M. Kobayashi, and K. Uchida. 2002. 15-Deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. Journal of Biological Chemistry 277: 10459–10466.PubMedCrossRef

Scher, J.U., and M.H. Pillinger. 2005. 15d-PGJ2: The anti-inflammatory prostaglandin? Clinical Immunology 114: 100–109.PubMedCrossRef

Liu, X., H. Yu, L. Yang, C. Li, and L. Li. 2012. 15-Deoxy-Delta(12,14)-prostaglandin J(2) attenuates the biological activities of monocyte/macrophage cell lines. European Journal of Cell Biology 91: 654–661.PubMedCrossRef

Prasad, R., S. Giri, A.K. Singh, and I. Singh. 2008. 15-Deoxy-delta12,14-prostaglandin J2 attenuates endothelial-monocyte interaction: Implication for inflammatory diseases. J Inflamm (Lond) 5: 14.CrossRef

10.

Nosjean, O., and J.A. Boutin. 2002. Natural ligands of PPARgamma: Are prostaglandin J(2) derivatives really playing the part? Cellular Signalling 14: 573–583.PubMedCrossRef

11.

Mochizuki, M., Y. Ishii, K. Itoh, et al. 2005. Role of 15-deoxy delta(12,14) prostaglandin J2 and Nrf2 pathways in protection against acute lung injury. American Journal of Respiratory and Critical Care Medicine 171: 1260–1266.PubMedCrossRef

12.

Cloutier, A., I. Marois, D. Cloutier, C. Verreault, A.M. Cantin, and M.V. Richter. 2012. The prostanoid 15-deoxy-Delta12,14-prostaglandin-j2 reduces lung inflammation and protects mice against lethal influenza infection. The Journal of Infectious Diseases 205: 621–630.PubMedCrossRef

13.

Roberts, L.J., and J.D. Morrow. 2000. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radical Biology & Medicine 28: 505–513.CrossRef

14.

Wright, R.M., L.A. Ginger, N. Kosila, et al. 2004. Mononuclear phagocyte xanthine oxidoreductase contributes to cytokine-induced acute lung injury. American Journal of Respiratory Cell and Molecular Biology 30: 479–490.PubMedCrossRef

15.

Haschke, M., Y.L. Zhang, C. Kahle, et al. 2007. HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. Clinical Chemistry 53: 489–497.PubMedCrossRef

16.

Rajakariar, R., M. Hilliard, T. Lawrence, et al. 2007. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci USA 104: 20979–20984.PubMedCrossRef

17.

Marx, N., F. Mach, A. Sauty, et al. 2000. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. Journal of Immunology 164: 6503–6508.

18.

Marx, N., G.K. Sukhova, T. Collins, P. Libby, and J. Plutzky. 1999. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125–3131.PubMedCrossRef

19.

Kawahito, Y., M. Kondo, Y. Tsubouchi, et al. 2000. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. The Journal of Clinical Investigation 106: 189–197.PubMedCrossRef

20.

Shan, Z.Z., K. Masuko-Hongo, S.M. Dai, H. Nakamura, T. Kato, and K. Nishioka. 2004. A potential role of 15-deoxy-delta(12,14)-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis. Journal of Biological Chemistry 279: 37939–37950.PubMedCrossRef

21.

Combs, C.K., D.E. Johnson, J.C. Karlo, S.B. Cannady, and G.E. Landreth. 2000. Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. The Journal Of Neuroscience: The official journal of the Society for Neuroscience 20: 558–567.

22.

Reddy, R.C., V.G. Keshamouni, S.H. Jaigirdar, et al. 2004. Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor-gamma ligands. American Journal of Physiology. Lung Cellular and Molecular Physiology 286: L613–L619.PubMedCrossRef

23.

Wang, A.C., X. Dai, B. Luu, and D.J. Conrad. 2001. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. American Journal of Respiratory Cell and Molecular Biology 24: 688–693.PubMedCrossRef

24.

Urade, Y., M. Ujihara, Y. Horiguchi, et al. 1990. Mast cells contain spleen-type prostaglandin D synthetase. Journal of Biological Chemistry 265: 371–375.PubMed

25.

Mahmud, I., N. Ueda, H. Yamaguchi, et al. 1997. Prostaglandin D synthase in human megakaryoblastic cells. Journal of Biological Chemistry 272: 28263–28266.PubMedCrossRef

26.

Tanaka, K., K. Ogawa, K. Sugamura, M. Nakamura, S. Takano, and K. Nagata. 2000. Cutting edge: Differential production of prostaglandin D2 by human helper T cell subsets. Journal of Immunology 164: 2277–2280.

27.

Gandhi, U.H., N. Kaushal, K.C. Ravindra, et al. 2011. Selenoprotein-dependent up-regulation of hematopoietic prostaglandin D2 synthase in macrophages is mediated through the activation of peroxisome proliferator-activated receptor (PPAR) gamma. Journal of Biological Chemistry 286: 27471–27482.PubMedCrossRef

28.

Quinkler, M., I.J. Bujalska, J.W. Tomlinson, D.M. Smith, and P.M. Stewart. 2006. Depot-specific prostaglandin synthesis in human adipose tissue: A novel possible mechanism of adipogenesis. Gene 380: 137–143.PubMedCrossRef

29.

Urade, Y., and O. Hayaishi. 2000. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochimica et Biophysica Acta 1482: 259–271.PubMedCrossRef

30.

Ide, T., K. Egan, L.C. Bell-Parikh, and G.A. FitzGerald. 2003. Activation of nuclear receptors by prostaglandins. Thrombosis Research 110: 311–315.PubMedCrossRef

31.

Nagata, K., and H. Hirai. 2003. The second PGD(2) receptor CRTH2: Structure, properties, and functions in leukocytes. Prostaglandins, Leukotrienes, and Essential Fatty Acids 69: 169–177.PubMedCrossRef

32.

Rossi, A., P. Kapahi, G. Natoli, et al. 2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403: 103–108.PubMedCrossRef

33.

Oliva, J.L., D. Perez-Sala, A. Castrillo, et al. 2003. The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras. Proc Natl Acad Sci USA 100: 4772–4777.PubMedCrossRef

34.

Kansanen, E., A.M. Kivela, and A.L. Levonen. 2009. Regulation of Nrf2-dependent gene expression by 15-deoxy-Delta12,14-prostaglandin J2. Free Radical Biology & Medicine 47: 1310–1317.CrossRef

35.

Jiang, C., A.T. Ting, and B. Seed. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82–86.PubMedCrossRef

36.

Ricote, M., A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass. 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79–82.PubMedCrossRef

37.

Zhang, X., J.M. Wang, W.H. Gong, N. Mukaida, and H.A. Young. 2001. Differential regulation of chemokine gene expression by 15-deoxy-delta 12,14 prostaglandin J2. Journal of Immunology 166: 7104–7111.

38.

Thieringer, R., J.E. Fenyk-Melody, C.B. Le Grand, et al. 2000. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. Journal of Immunology 164: 1046–1054.

39.

Azuma, Y., M. Shinohara, P.L. Wang, and K. Ohura. 2001. 15-Deoxy-delta(12,14)-prostaglandin J(2) inhibits IL-10 and IL-12 production by macrophages. Biochemical and Biophysical Research Communications 283: 344–346.PubMedCrossRef

40.

Bowman, C.M., R.N. Harada, and J.E. Repine. 1983. Hyperoxia stimulates alveolar macrophages to produce and release a factor which increases neutrophil adherence. Inflammation 7: 331–338.PubMedCrossRef

41.

Harada, R.N., A.E. Vatter, and J.E. Repine. 1984. Macrophage effector function in pulmonary oxygen toxicity: Hyperoxia damages and stimulates alveolar macrophages to make and release chemotaxins for polymorphonuclear leukocytes. Journal of Leukocyte Biology 35: 373–383.PubMed

42.

Negishi, M., T. Koizumi, and A. Ichikawa. 1995. Biological actions of delta 12-prostaglandin J2. Journal of Lipid Mediators and Cell Signalling 12: 443–448.PubMedCrossRef

43.

Fitzpatrick, F.A., and M.A. Wynalda. 1983. Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro. Journal of Biological Chemistry 258: 11713–11718.PubMed

44.

Hirata, Y., H. Hayashi, S. Ito, et al. 1988. Occurrence of 9-deoxy-delta 9, delta 12–13,14-dihydroprostaglandin D2 in human urine. Journal of Biological Chemistry 263: 16619–16625.PubMed

45.

Kikawa, Y., S. Narumiya, M. Fukushima, H. Wakatsuka, and O. Hayaishi. 1984. 9-Deoxy-delta 9, delta 12–13,14-dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma. Proc Natl Acad Sci USA 81: 1317–1321.PubMedCrossRef

46.

Heinemann, A., R. Schuligoi, I. Sabroe, A. Hartnell, and B.A. Peskar. 2003. Delta 12-prostaglandin J2, a plasma metabolite of prostaglandin D2, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis. Journal of Immunology 170: 4752–4758.

47.

Klawitter, J., M. Haschke, T. Shokati, J. Klawitter, and U. Christians. 2011. Quantification of 15-F2t-isoprostane in human plasma and urine: Results from enzyme-linked immunoassay and liquid chromatography/tandem mass spectrometry cannot be compared. Rapid Communications in Mass Spectrometry: RCM 25: 463–468.PubMedCrossRef

48.

Seok J, Warren HS, Cuenca AG, et al. 2013. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110: 3507–12.

Titel: Early Increase in Alveolar Macrophage Prostaglandin 15d-PGJ2 Precedes Neutrophil Recruitment into Lungs of Cytokine-Insufflated Rats
verfasst von: Ana Fernandez-Bustamante
Jelena Klawitter
Paul Wilson
Nancy D. Elkins
Amanda Agazio
Takahiro Shibata
Koji Uchida
Uwe Christians
John E. Repine
Publikationsdatum: 01.10.2013
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 5/2013
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-013-9635-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

ABSTRACT

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

Magnolol Inhibits LPS-Induced Inflammatory Response in Uterine Epithelial Cells

Ultrasound-Targeted Microbubble Destruction Enhances Human β-Defensin 3 Activity Against Antibiotic-Resistant Staphylococcus Biofilms

Ketamine Inhibits Calcium Elevation and Hydroxyl Radical and Nitric Oxide Production in Lipopolysaccharide-Stimulated NR8383 Alveolar Macrophages

RNA Interference Targeting p110β Reduces Tumor Necrosis Factor-Alpha Production in Cellular Response to Wear Particles In vitro and Osteolysis In vivo

The Protective Effect of Recombinant FomA-expressing Lactobacillus acidophilus Against Periodontal Infection